pdf   xlsx method abbreviations

metastatic/advanced - colorectal cancer (mCRC), atezolizumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.00 [0.73, 1.37]< 10%1 study (1/-)50.0 %NAnot evaluable crucial-
progression or deaths (PFS) 1.39 [1.00, 1.94]< 10%1 study (1/-)2.6 %NAnot evaluable important-
objective responses (ORR) 1.00 [0.14, 7.26]> 10%1 study (1/-)50.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 0.62 [0.18, 2.22]< 10%1 study (1/-)76.7 %NAnot evaluable non important-
AE (grade 3-4) 0.33 [0.18, 0.63]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
AE leading to death (grade 5) 0.22 [0.01, 4.90]< 10%1 study (1/-)82.8 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 0.49 [0.14, 1.72]< 10%1 study (1/-)86.8 %NAnot evaluable non important-
SAE (any grade) 0.69 [0.32, 1.48]< 10%1 study (1/-)83.1 %NAnot evaluable non important-
STRAE (any grade) 0.67 [0.24, 1.88]< 10%1 study (1/-)77.9 %NAnot evaluable non important-
TRAE (any grade) 0.05 [0.01, 0.16]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE (grade 3-4) 0.12 [0.05, 0.26]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Increased lipase level TRAE (grade 3-4) 0.89 [0.05, 14.43]< 10%1 study (1/-)53.3 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

hepatitis (Autoimmune) AE (grade 3-4) 3.61 [0.16, 81.33]< 10%1 study (1/-)21.2 %NAnot evaluable non important-
Abdominal pain AE (grade 3-4) 1.19 [0.26, 5.50]< 10%1 study (1/-)41.0 %NAnot evaluable non important-
Acute kidney injury AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Anaemia AE (grade 3-4) 0.22 [0.01, 4.90]< 10%1 study (1/-)82.8 %NAnot evaluable non important-
Arthralgia AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Asthenia AE (grade 3-4) 1.80 [0.16, 20.18]< 10%1 study (1/-)31.9 %NAnot evaluable non important-
Back pain AE (grade 3-4) 5.48 [0.27, 111.16]< 10%1 study (1/-)13.7 %NAnot evaluable non important-
Colitis AE (grade 3-4) 1.79 [0.06, 53.98]< 10%1 study (1/-)37.1 %NAnot evaluable non important-
Constipation AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Cough AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Decreased appetite AE (grade 3-4) 0.22 [0.01, 4.90]< 10%1 study (1/-)82.8 %NAnot evaluable non important-
Dermatitis acneiform AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 0.17 [0.02, 1.47]< 10%1 study (1/-)94.5 %NAnot evaluable non important-
Dysgeusia AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Dysphonia AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Dyspnoea AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Fatigue AE (grade 3-4) 0.61 [0.19, 2.02]< 10%1 study (1/-)78.9 %NAnot evaluable non important-
Guillain-Barré syndrome AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Headache AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Hypertension AE (grade 3-4) 0.24 [0.06, 0.91]< 10%1 study (1/-)98.2 %NAnot evaluable non important-
Increased ALT AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Infusion-related reaction AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Intestinal perforation AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Mucosal inflammation AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Myalgia AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Nausea AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) 0.04 [0.00, 0.77]< 10%1 study (1/-)98.3 %NAnot evaluable non important-
Peripheral neuropathy AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Peripheral oedema AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Pneumonitis AE (grade 3-4) 1.79 [0.06, 53.98]< 10%1 study (1/-)37.1 %NAnot evaluable non important-
Pruritus AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Pyrexia AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Rash AE (grade 3-4) 0.44 [0.04, 4.93]< 10%1 study (1/-)74.6 %NAnot evaluable non important-
Rash maculopapular AE (grade 3-4) 0.44 [0.01, 13.33]< 10%1 study (1/-)67.8 %NAnot evaluable non important-
Sepsis AE (grade 3-4) 0.22 [0.01, 4.90]< 10%1 study (1/-)82.8 %NAnot evaluable non important-
Stomatitis AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Thrombocytopenia AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Vomiting AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-
Weight decreased AE (grade 3-4) 0.89 [0.02, 45.29]< 10%1 study (1/-)52.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons